Viking Therapeutics
VKTXViking Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and endocrine disorders.
Earnings
Next report
Date not yet announcedFinancials
Q1 2026Valuation & ratios
Competitors
By market cap
Profile
Viking Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and endocrine disorders. The company leverages its expertise in receptor-subtype selective agonists to create first-in-class or best-in-class treatments for large unmet medical needs. Its core value proposition lies in its diversified pipeline of small molecule and peptide candidates targeting obesity, NASH/MASH, and rare inherited neurological disorders.
A clinical-stage innovator with a high-potential pipeline in the competitive incretin and TRß agonist markets, currently transitioning from mid-stage to pivotal Phase 3 trials.
FAQ
- What is Viking Therapeutics's market cap?
- Viking Therapeutics (VKTX) has a market capitalization of $3.4B and trades on NASDAQ.
- Who are Viking Therapeutics's competitors?
- Viking Therapeutics's key competitors include Madrigal Pharmaceuticals, Inc., MBX Biosciences, Inc. Common Stock, Vivani Medical, Inc. Common Stock (DE), and others. These companies compete in similar markets and product categories.
- Who does Viking Therapeutics partner with?
- Viking Therapeutics's notable partners include Ligand Pharmaceuticals Incorporated, Corden Pharma Colorado, Inc..
- Where is Viking Therapeutics headquartered?
- Viking Therapeutics is headquartered in United States of America and employs approximately 30 people. It has been publicly traded since 2015.